Study M770
Study name | Duan JJ 2021 |
Title | Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment |
Overall design | The aim of this study was to investigate the characteristics of gut microbiome that associated with the escitalopram treatment responses in the chronic unpredictable mild stress (CUMS) model. After the initial 4 weeks of exposure to mild stress, the animals were administered either escitalopram (10 mg/kg) or vehicle for another 4 weeks. Drug or vehicle was administrated by oral gavage once daily for 4 weeks during stress. C57BL/6 mice were divided into the following 2 groups (n = 8 in each group): (1) responder group (mice with a minimum 10% increase in sucrose intake compared to anhedonic level after treatment; n = 7), and (2) non-responder group (mice not response to escitalopram treatment after treatment; n = 9). Disturbances of serum metabolic signatures between both groups were identified by GC-MS based metabolomics. |
Study Type | Type4; |
Data available | Unavailable |
Organism | Mouse; C57BL/6 mouse; |
Categories of depression | Animal model; Chronic mild stress model; Chronic mild stress model; |
Criteria for depression | Sucrose preference test, forced swimming test |
Sample size | 16 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; GC-MS: 7890 A gas chromatography system coupled to Agilent 5975 C MSD system (Agilent, CA); |
PMID | |
DOI | |
Citation | Duan J, Huang Y, Tan X, et al. Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment. Transl Psychiatry. 2021 May 20;11(1):303. |
Metabolite | L-Aspartic acid; Ethanolamine; Alpha-Tocopherol; O-Phosphoethanolamine; Epinephrine; Cysteinylglycine; Oxamic acid; MG(18:0/0:0/0:0); 2-Aminobenzoic acid; Stigmasterol; |
